
In today’s briefing:
- Japan Activist Watch | Square Enix, DaitoTrust, Iriso & INES
- Seibu Holdings (TSE: 9024) – Asset-Rich Platform With Significant Upside from Monetization
- How Apple Accidentally Built China’s Tech Superpower and Can’t Escape with Patrick McGee
- Micron Q325 Earnings: NAND’s Surprising Rebound While HBM Already @$6 Billion Annual Run Rate.
- Commonwealth Bank of Australia – The Overnight Report: Geopolitical Crescendo
- The end of the UK’s ‘bailout era’
- Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization
- Memory Monitor: Micron Reinforces AI Memory Tailwinds, But Broader Supply Chain Recovery Gradual
- Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness
- AAON Secures $200M in Liquid Cooling Orders—Is This the Future of AI Data Centers?

Japan Activist Watch | Square Enix, DaitoTrust, Iriso & INES
- Activist investors 3D Investment Partners and Dalton Investments have both taken meaningful stakes in Square Enix – highlights capital inefficiency and poor margin profile
- Daito Trust sits on over ¥100bn in net cash, an arguably excessive cushion for a mature operator with steady cash flows. Silchester have taken note
- Iriso Electronic and INES both trade below book value. Attractive value plays for small cap funds.
Seibu Holdings (TSE: 9024) – Asset-Rich Platform With Significant Upside from Monetization
- Seibu’s FY25 results were buoyed by a ¥350 bn real estate securitization, driving operating profit to ¥263 bn and showcasing the deep value embedded in its property portfolio.
- Management plans to monetize ~¥1.35 trillion of urban assets over the next 3–5 years, shift to a capital-light hotel model, and revitalize transport margins via fare revisions.
- Even at the current price of ¥4,868, Seibu trades at a ~45% discount to its fully adjusted SoTP value (~¥8,873/share)—implying substantial re-rating potential if monetization proceeds as planned.
How Apple Accidentally Built China’s Tech Superpower and Can’t Escape with Patrick McGee
- ndia does not have a top-down method for executing a five year plan like China does
- hina’s supply chain is vast and highly competitive, with India unlikely to replicate its success
- hina wants technology transfer to be one-way gate, inhibiting India’s ability to compete
- atrick Magee studied religion before becoming a financial journalist and eventually writing about Apple’s dependence on China
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
Micron Q325 Earnings: NAND’s Surprising Rebound While HBM Already @$6 Billion Annual Run Rate.
- Q325 revenues of $9.3 billion, up 15% QoQ and up 37% YoY and $500 million above the guided midpoint. This represented a new quarterly revenue record for the company
- Micron forecasted current quarter revenues of $10.7 billion, up 15% QoQ, with gross margin of 42%, up 300 basis points sequentially
- HBM negotiations for 2026 supply & pricing still ongoing. Could Micron be holding out for a better deal?
Commonwealth Bank of Australia – The Overnight Report: Geopolitical Crescendo
- A global perspective on what happened overnight
The end of the UK’s ‘bailout era’
- UK government owned Royal Bank of Scotland (RBS) for 17 years, impacting taxpayer finances
- RBS’s aggressive expansion and risky acquisitions led to vulnerabilities and exposure to toxic assets
- Government bailed out RBS with £45.5 billion, taking an 84% stake in the bank and preventing a collapse in 2008.
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization
- Clarity Pharmaceuticals Ltd (CU6 AU) initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.
- The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&D tax incentive. This provides cash runway through 2H26.
- Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization.
Memory Monitor: Micron Reinforces AI Memory Tailwinds, But Broader Supply Chain Recovery Gradual
- Micron Results Beat Across the Board, AI Product Mix Drives Gross Margin Upside
- No Evidence Yet of Hyperscaler Pullback, But No Significant Increase in Outlook Either
- Conclusion: AI-Driven Strength Continues, But Divergence Across the Memory Supply Chain Persists
Novartis CEO: Medical Innovation, Tech Partnerships, and European Competitiveness
- The CEO of Novartis, with a medical background, emphasizes the importance of focusing on breakthrough innovations and patient impact in leading the company
- Implemented changes to focus on innovative medicines by spinning off non-core businesses, leading to unlocking significant value for the company
- Novartis structures R&D differently by having a strategy and growth function, focusing on key therapeutic areas, and investing in advanced technology platforms like radio ligand therapies and cell and gene therapies
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.
AAON Secures $200M in Liquid Cooling Orders—Is This the Future of AI Data Centers?
- AAON Inc.’s first quarter of 2025 results highlight a mix of positive growth and operational challenges, painting a complex picture for potential investors.
- The company’s core strategic pillars focus on innovation, sustainable growth, and operational excellence, positioning it for long-term advancement.
- This focus is evident in its commitment to developing new products, like heat pumps and data center cooling solutions, which align with its innovative goals.